JAMA Oncology Author Interviews
Health & Fitness:Medicine
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy for Metastatic NSCLC
Interview with Naiyer A. Rizvi, MD, author of Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial
Create your
podcast in
minutes
It is Free